These findings contribute to our understanding of the mechanisms underlying the anti-tumor activity of SJ-C1044 and provide a basis for further investigations and clinical developments of this multi-kinase inhibitor as an effective treatment option for RAS or BRAF mutant cancers. This evidence concerns the gene BRAF and neoplasm.